PRO MEDICUS LIMITED (PME)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

PME

PME - PRO MEDICUS LIMITED

FNArena Sector : Medical Equipment & Devices
Year End: June
GICS Industry Group : Health Care Equipment & Services
Debt/EBITDA: 0.01
Index: ASX50 | ASX100 | ASX200 | ASX300 | ALL-ORDS | ALL-TECH

Pro Medicus is an imaging IT company providing a range of radiology software and services, medical accounting and clinical reporting to the health care sector. Founded in 1983, the company listed on the ASX in 2000.

LAST PRICE CHANGE +/- CHANGE % VOLUME

$313.50

15 Aug
2025

-2.190

OPEN

$323.50

-0.69%

HIGH

$323.50

274,054

LOW

$310.52

TARGET
$300.267 -4.2% downside
Franking for last dividend paid out: 100%
OTHER COMPANIES IN THE SAME SECTOR
4DX . AT1 . AYA . BB1 . BRN . CAT . CBL . CGS . CMP . COH . CSX . CU6 . CVB . CYC . EBR . EMV . EYE . FPH . IME . IMR . IPD . LDX . MX1 . NAN . ONE . PCK . PEB . PGC . RMD . SOM . TRJ . UBI .
FNARENA'S MARKET CONSENSUS FORECASTS
PME: 1
Title FY24
Actual		 FY25
Actual		 FY26
Forecast		 FY27
Forecast
EPS (cps) xxx 110.3 152.6 xxx
DPS (cps) xxx 55.0 76.6 xxx
EPS Growth xxx 39.1% 38.4% xxx
DPS Growth xxx 37.5% 39.3% xxx
PE Ratio xxx N/A 208.2 xxx
Dividend Yield xxx N/A 0.2% xxx
Div Pay Ratio(%) xxx 49.9% 50.2% xxx

Dividend yield today if purchased 3 years ago: 1.02%

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

 0.17

Estimated Dividend Growth
(Average Of Past Three Years)

  %

Amount Invested

 $ 

Tell Me The Dividend After This Many Years
Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages

Last ex-div: 04/09 - ex-div 22c (franking 100%)

HISTORICAL DATA ARE ALL IN AUD
Copyright © 2025 FactSet UK Limited. All rights reserved
Title 202020212022202320242025
EPS Basic xxxxxxxxxxxxxxx110.3
DPS All xxxxxxxxxxxxxxx55.0
Sales/Revenue xxxxxxxxxxxxxxx213.0 M
Book Value Per Share xxxxxxxxxxxxxxx246.0
Net Operating Cash Flow xxxxxxxxxxxxxxx118.9 M
Net Profit Margin xxxxxxxxxxxxxxx54.10 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 202020212022202320242025
Return on Capital Employed xxxxxxxxxxxxxxx51.82 %
Return on Invested Capital xxxxxxxxxxxxxxx51.46 %
Return on Assets xxxxxxxxxxxxxxx38.65 %
Return on Equity xxxxxxxxxxxxxxx51.82 %
Return on Total Capital xxxxxxxxxxxxxxx70.24 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx69.3 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 202020212022202320242025
Short-Term Debt xxxxxxxxxxxxxxx1 M
Long Term Debt xxxxxxxxxxxxxxx2 M
Total Debt xxxxxxxxxxxxxxx2 M
Goodwill - Gross xxxxxxxxxxxxxxx-
Cash & Equivalents - Generic xxxxxxxxxxxxxxx209 M
Price To Book Value xxxxxxxxxxxxxxx115.89

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 202020212022202320242025
Capex xxxxxxxxxxxxxxx7.4 M
Capex % of Sales xxxxxxxxxxxxxxx3.46 %
Cost of Goods Sold xxxxxxxxxxxxxxx44 M
Selling, General & Admin. Exp & Other xxxxxxxxxxxxxxx11 M
Research & Development xxxxxxxxxxxxxxx-
Investments - Total xxxxxxxxxxxxxxx7 M

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

-0.1

No. Of Recommendations

6
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Bell Potter

xx/xx/xxxx

3

xxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Morgans

xx/xx/xxxx

4

xxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Macquarie

xx/xx/xxxx

3

xxxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Citi

15/08/2025

5

Sell

$220.00

-29.82%

Pro Medicus’ FY25 result was broadly in line with Citi’s expectations, with revenue up 32%, earnings (EBIT) up 39% and profit up 39%, supported by record $67m in contract wins.

The broker expects FY26 profit growth of 41%, driven by these wins and contained operating cost growth of 16%. North American market share has risen to around 10% from 7% a year ago.

Following its move into Cardiology, the company will launch a Digital Pathology product in Q4 2025, potentially lifting its total addressable market by 10-15%, observe the analysts.

The company is positioning as a platform for AI algorithm commercialisation, explains the broker, with initiatives including a breast cancer detection algorithm, a partnership with Elucid, and collaborations with third parties.

Citi adjusts FY26-27 EPS forecasts by 1% and -7%, respectively, and lifts its target price to $220 from $165, retaining a Sell rating.

FORECAST
Citi forecasts a full year FY26 dividend of 78.00 cents and EPS of 155.30 cents.
Citi forecasts a full year FY27 dividend of 103.00 cents and EPS of 206.30 cents.

Morgan Stanley

xx/xx/xxxx

1

xxxxxxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Ord Minnett

xx/xx/xxxx

3

xxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial
Access Stockbroker Research History >
EXTRA COVERAGE
Display All Commentary

No. Of Recommendations

2

Please note: unlike Broker Call Report, BC Extra is not updated daily. The info you see might not be the latest. FNArena does its best to update ASAP.

BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Moelis

xx/xx/xxxx

3

xxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Wilsons

18/08/2025

1

Upgrade to Overweight from Market Weight

$350.00

11.64%

Wilsons notes Pro Medicus's FY25 result was solid on revenue and outstanding on margin leverage, showing it can lift profits while penetrating larger US integrated delivery networks.

Total addressable market for cardiology was lifted to 670m scans, of which 85% is serviceable in full-stack model. Digital pathology was confirmed for FY26 and the broker views it as offering future upside optionality.

Minimal changes to the broker's revenue forecasts but margin is conservatively expected to increase by 60bps in FY26 and 76bps in FY27.

Target lifted to $350 from $325. Rating upgraded to Overweight from Market Weight.

FORECAST
Wilsons forecasts a full year FY26 dividend of 74.30 cents and EPS of 150.30 cents.
Wilsons forecasts a full year FY27 dividend of 102.50 cents and EPS of 205.00 cents.
Access Extra Coverage Research History >

PME STOCK CHART

FNArena News on PME

1
Australian Broker Call *Extra* Edition – Aug 18, 2025

10:30 AM - Daily Market Reports
2
FNArena Corporate Results Monitor – 15-08-2025

Aug 15 2025 - Australia
3
Next Week At A Glance – 18-22 Aug 2025

Aug 15 2025 - Weekly Reports
4
Rudi’s View: BlueScope Steel, IGO, GrainCorp, Pilbara Minerals, Santos & More

Aug 14 2025 - Rudi's View
5
Life360, Not Just Another App?

Aug 14 2025 - Australia

Latest Medical Equipment & Devices News

1
ResMed’s New Level Of Support

Jul 29 2025 - Technicals
2
Strength To ‘AI’ Strength For Pro Medicus

Jul 10 2025 - Australia
3
Cochlear Downgrades Ahead Of New Launches

Jun 19 2025 - Australia
4
Fisher & Paykel Healthcare’s Tariffs Annoyance

Jun 04 2025 - Australia
5
ResMed’s Margin Expansion & Tariff Exemption

Apr 28 2025 - Australia
6
Trend Remains Up For Catapult International

Feb 18 2025 - Technicals
7
ESG Focus: Top ASX Companies, Superbugs & Hydrogen

Feb 07 2025 - ESG Focus
8
ResMed Shakes Off GLP-1 Scare

Feb 04 2025 - Australia
9
ResMed: Another Positive Quarterly Surprise?

Jan 30 2025 - Australia
10
The Trend Remains Pro Medicus’ Friend

Jan 16 2025 - Technicals